Longbio Pharma

Explore the latest insights on Longbio Pharma and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Longbio Pharma’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Explore the latest insights on Longbio Pharma and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Longbio Pharma's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed
Company

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed

Roche (SWX: ROP; OTCMKTS: RHHBY) today reported its financial results for the first nine months of 2026. Group sales reached CHF 46.493 billion (~USD 56.3 billion), a 6% increase at…

European Commission Approves Novartis' Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe

European Commission Approves Novartis’ Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

CompanyDrug

LongBio Pharma Secures FDA IND Approval for Novel Anti-IgE Antibody LP-003 in Peanut Allergy, Expanding Global Allergic Disease Pipeline

CompanyDrug

LongBio Pharma’s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
CompanyDeals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies
CompanyDeals

LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies

CompanyDeals

Longbio Pharma Secures RMB 100 Million in Series B2 Financing to Advance Clinical Programs

CompanyDeals

Innovent Biologics’ Altruist Biologics Partners with Longbio Pharma in RMB 500 Million Deal

CompanyDeals

LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development